GOOIMEER 2-35, NARRDEN, P7
Reg. FD
Reports Full Year 2025 Financial Results and Provides Corporate Update
Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
Provides Corporate Update and Reports Third Quarter Financial Results
Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
Material Contracts
Provides Corporate Update and Reports Second Quarter Financial Results
FY 2024
Q3
Q2
Q1
FY 2023
Amended Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload